ArticleAnnals of surgical oncology2021
Current Surgical Management of Inflammatory Breast Cancer.
Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Breast Reconstruction Use and Impact on Surgical and Oncologic Outcomes Amongst Inflammatory Breast Cancer Patients-A Systematic Review.Current oncology (Toronto, Ont.) · 2023Pooled it
- Investigating the Prognostic Impact of Postpartum Diagnosis in Women with De Novo Stage IV Inflammatory Breast Cancer.Annals of surgical oncology · 2025Article
- Inflammatory breast cancer, best practice in the community setting.NPJ breast cancer · 2025Review
- Immediate Breast Reconstruction for Inflammatory Breast Carcinoma: A Scoping Review.Journal of surgical oncology · 2025Article
- Double trouble, managing bilateral inflammatory breast cancer: a case report.Frontiers in oncology · 2025Article
- Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership: Consensus and Opportunities.Annals of surgical oncology · 2024Article
- Shifting neoadjuvant chemotherapy treatment paradigms for breast cancer and its impact on axillary nodal management for clinically node-negative patients.Gland surgery · 2024Article
- Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024.Breast care (Basel, Switzerland) · 2024Review
- Comprehensive Characterization of Immune Cell Infiltration Characteristics and Drug Sensitivity Analysis in Inflammatory Breast Cancer Based on Bioinformatic Strategy.Biochemical genetics · 2024Article
- Improved Rate of Negative Margins for Inflammatory Breast Cancer Using Intraoperative Frozen Section Analysis.Cancers · 2023Article
- Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023.Breast care (Basel, Switzerland) · 2023Review
- Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting.Cancers · 2023Article
- Contemporary Trends in Breast Reconstruction Use and Impact on Survival Among Women with Inflammatory Breast Cancer.Annals of surgical oncology · 2022Article
- Modified Radical Mastectomy in De Novo Stage IV Inflammatory Breast Cancer.Annals of surgical oncology · 2022Article
- Photodynamic therapy in breast cancer treatment.Journal of applied biomedicine · 2022Review
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.Breast care (Basel, Switzerland) · 2022Review
- Remifentanil combined with dexmedetomidine on the analgesic effect of breast cancer patients undergoing modified radical mastectomy and the influence of perioperative T lymphocyte subsets.Frontiers in surgery · 2022Article
- 22nd Annual Virtual Meeting of the American Society of Breast Surgeons: Science, Innovation, and Practice Changes.Annals of surgical oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory breast cancer (IBC) is a rare and aggressive breast cancer characterized by erythema and edema of at least one-third of the breast. The diagnosis remains a clinical one. Standard of care involves trimodality therapy with anthracycline-based neoadjuvant chemotherapy and human epidermal growth factor receptor 2 (HER2)-directed therapy if HER2 positive, followed by modified radical mastectomy and post-mastectomy radiation therapy to the chest wall in addition to regional nodal basins including supraclavicular and internal mammary nodes. Current evidence does not support de-escalation of surgical therapy in the breast and axilla in IBC, and positive surgical margins have been associated with worse outcomes. Furthermore, sentinel node biopsy for axillary staging has a high false negative rate prohibiting its use in IBC. Delayed reconstruction is recommended for IBC due to a high recurrence rate and a potential for delay in adjuvant therapy. Contralateral prophylactic mastectomy may be considered at the time of delayed reconstruction. In this paper, we discuss available evidence and controversies in the current surgical management of patients with IBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.